Product news

Share this article:

The FDA has approved UCB and Sanofi-Aventis' NDA for Xyzal (levocetirizine dihydrochloride) 0.5 mg/ml oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria. Xyzal tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older.

King Pharmaceuticals announced its has launched a tablet version of its ACE inhibitor
Altace (ramipril). The company will continue to make available Altace capsules.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions